Bladder Cancer Weekly

December 09, 2024

Videos

Peer-to-Peer Clinical Conversations

Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski

Tracey Krupski

Tracey Krupski explores the implementation of tele-cystoscopy to improve access to bladder cancer care in resource-challenged areas.

View

Current Options for BCG Unresponsive NMIBC - Eugene Pietzak

Eugene J. Pietzak

Sam Chang hosts Eugene Pietzak to discuss treatment options for BCG-unresponsive bladder cancer and the challenges of evaluating their comparative effectiveness.

View

Beyond the Abstracts

Modulation of the Tumor Microenvironment in Non-Muscle-Invasive Bladder Cancer by OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: Effects on Tumor-Associated Macrophages, Tumor-Infiltrating Lymphocytes, and Monoamine Oxidases - Beyond the Abstract

Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients - Beyond the Abstract

Conference Coverage

SUO 2024: Adjuvant Radiation Following Cystectomy: Underutilized Therapy?

SUO 2024: Management of the Bladder in Metastatic Patients Following Complete Response to Systemic Therapy: Is There a Role for Consolidative Local Therapy?

SUO 2024: The Evolution of First-Line Treatment for Metastatic Urothelial Cancer

SUO 2024: Precision in Urothelial Carcinoma: Overarching Theme 2 – ctDNA-Based Clinical Decision-Making in Urothelial Cancer: What Do We Know in 2024?

SUO 2024: A Personalized and Pragmatic Approach to (P)rehabilitation for Patients with Bladder Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

High-Risk Non-Muscle Invasive Bladder Cancer: outcomes of patients who cannot benefit from Standard of Care.

Virtual simulator for cystoscopy containing motion blur and bladder debris to aid the development of clinical tools.

IMFINZI® (durvalumab) Granted Priority Review in the US for Patients with Muscle-invasive Bladder Cancer

Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.

The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study.

Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytol

Long-term quality of life in patients with bladder cancer following radical cystectomy.

Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approach.

Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes.

The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer.

A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder

The Management of Non-Muscle-Invasive Bladder Cancer in a Veteran Patient Population: Issues and Recommendations.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login